Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY26 results · Oct–Dec 2025
Torrent Pharmaceuticals reported revenue from operations of ₹3,303.00 crore (up 17.6% from Q3 FY25) and net profit of ₹635.00 crore (up 26.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,303.00 | 2,809.00 | +17.6% | 3,302.00 | +0.0% |
| Other income | (13.00) | 33.00 | Turned loss | (27.00) | Loss narrowed |
| Total income | 3,290.00 | 2,842.00 | +15.8% | 3,275.00 | +0.5% |
| Profit before tax | 814.00 | 691.00 | +17.8% | 791.00 | +2.9% |
| Net profit for the period | 635.00 | 503.00 | +26.2% | 591.00 | +7.4% |
| EPS, basic (₹) | 18.77 | 14.88 | +26.1% | 17.45 | +7.6% |
| Net margin (%) | 19.2 | 17.9 | 17.9 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,599.00 | 2,377.00 | +9.3% | 2,762.00 | −5.9% |
| Other income | (8.00) | 3.00 | Turned loss | (27.00) | Loss narrowed |
| Total income | 2,591.00 | 2,380.00 | +8.9% | 2,735.00 | −5.3% |
| Profit before tax | 757.00 | 651.00 | +16.3% | 806.00 | −6.1% |
| Net profit for the period | 577.00 | 485.00 | +19.0% | 597.00 | −3.4% |
| EPS, basic (₹) | 17.04 | 14.33 | +18.9% | 17.64 | −3.4% |
| Net margin (%) | 22.2 | 20.4 | 21.6 |
Consolidated
- Filed with BSE
- 13 Feb 2026, 18:51 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2026, 18:51 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Audited
- Source
- XBRL filing on BSE